Type to search

Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix® in Highly Sensitized Kidney Transplant Patients | Pharmtech Focus
Hansa Biopharma Announces $70 Million Non-dilutive Product Finance Transaction With NovaQuest to Support Continued Development of the Company's Antibody-cleaving Enzyme Technology Platform | Pharmtech Focus
NICE Recommends Use of Hansa Biopharma's Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients | Pharmtech Focus